Vertex Pharmaceuticals | VRTX - Des Atouts

Prix De L'Action
430.29
Variation Quotidienne
-4.81 -1.11%
Mensuellement
-5.42%
Annuel
-12.87%
Q2 Prévisions
421.08




Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amgen USD 90.59B 445M 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
Biogen USD 29.44B 232M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Gilead Sciences USD 59.02B 490M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Insmed USD 2.26B 96.18M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
J&J USD 200.89B 1.68B 2026-03
Merck USD 129.55B 12.02B 2025-09
Moderna USD 12.34B 203M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
United Therapeutics USD 7.88B 528.9M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12